Viridian Therapeutics (VRDN) received FDA approval for veligrotug
VRDN — Updated Playbook & Thesis (Post-Approval)
AI Execution Summary (Updated): Viridian Therapeutics (VRDN) received FDA approval for veligrotug (Lumvoa™ / veligrotug-vvze) on June 26, 2026 — ahead of the June 30 PDUFA — for Thyroid Eye Disease (TED), with immediate commercial launch. The label covers both active and chronic TED, a major win vs. Tepezza. Management hosts a conference call Monday, June 29 at 8:00 a.m. ET. The stock closed June 26 at $17.90 (up ~2.93% on volume). With regulatory risk removed, strong cash (> $1B post-May raise), and positive subcutaneous data already in hand, this shifts to a post-approval execution / momentum play. Watch pre-market and conference call reaction for gap dynamics or institutional buying.
| Trade Scenario | Entry Trigger | Exit / Target Point | Return Profile | Probability |
|---|---|---|---|---|
| Base Case | Hold / dip to ~$17.00-17.50 | $19.50 – $20.50 | +10-15% | 55% |
| Bull Case (Squeeze) | Strong call reaction / volume | $22+ (near-term) | +20%+ | 30% |
| Bear Case (Sell News) | Gap down below $17 | $16.00 (stop zone) | -8-10% | 15% |
FDA approved Lumvoa™ (veligrotug-vvze) on June 26, 2026 for TED. First approved treatment with labeling covering both active and chronic TED. Immediate commercial availability — physicians can prescribe now. Conference call/webcast: Monday, June 29, 8:00 a.m. ET to discuss launch, pricing, and dynamics. European MAA review ongoing.
Closed June 26 at $17.90 (+2.93%, volume ~3.8M shares). Recent trading in the $17.38–18.38 range. Post-approval momentum setup — monitor for continuation or sell-the-news. Analyst targets remain well above current levels (consensus ~$36).
Viridian focuses on IGF-1R and FcRn inhibitors for autoimmune diseases, led by TED franchise.
IV anti-IGF-1R mAb. Positive Phase 3 THRIVE/THRIVE-2 data. Now approved with broad label and launch-ready infrastructure (field teams, supply chain, manufacturing). Shorter/fewer infusions vs. standard of care.
Subcutaneous half-life extended anti-IGF-1R. Both REVEAL-1 (active) and REVEAL-2 (chronic) read out positive in 2026 (Q1/Q2), meeting primaries with strong proptosis/diplopia responses and favorable safety (low hearing impairment). BLA planned for Q1 2027 — potential first SC autoinjector option.
Cash ~$762M as of March 31, 2026 + ~$335M net proceeds from May 2026 upsized equity + convertible notes offering. Total war chest well over $1B. Strong runway for launch and pipeline with minimal near-term dilution risk.
~$2B U.S. TED market (primarily Tepezza). Broad label + convenience advantages position Lumvoa for rapid adoption. Peak sales potential substantial.
Risk Disclaimer: This is for educational/informational purposes only and is not financial, investment, or trading advice. Stocks involve substantial risk of loss. Do your own due diligence and consult professionals. Markets can gap on news.
Comments
Post a Comment